摘要
目的 探讨异丙托溴铵联合布地奈德治疗小儿急性喘息性支气管炎的效果。方法 选取2020年1月至2023年1月安徽省亳州市蒙城县第一人民医院收治的82例小儿急性喘息性支气管炎患儿作为本次研究对象,借助随机数字表法将其分为对照组和研究组,每组41例,2组患儿治疗前均给予雾化治疗时需要按照严格雾化治疗标准操作并给予患儿心理安抚,对照组给予布地奈德雾化治疗,研究组在对照组的基础上联合异丙托溴铵治疗,评价患儿临床疗效、临床症状改善情况、免疫功能及不良反应情况。结果 研究组临床疗效高于对照组(P<0.05);研究组咳嗽、气喘、哮鸣音及湿啰音消失时间短于对照组(P<0.05);治疗前组间免疫功能指标水平差异(P>0.05),治疗后研究组CD3^(+)、CD4^(+)、CD4^(+)/CD8^(+)水平高于对照组(P<0.05),而CD8^(+)水平低于对照组(P<0.05);研究组不良反应率虽然低于对照组,但组间差异无统计学意义(P>0.05)。结论 小儿急性喘息性支气管炎患儿以异丙托溴铵联合布地奈德治疗,临床疗效理想,且安全性高,可有效缓解临床症状、体征,改善免疫功能,促进生活质量提升,可有效提高患者的雾化吸入治疗依从性,提高家长满意度,该联合疗法具有较高临床应用价值。
Objective To investigate the effect of ipratropium bromide combined with budesonide on children with acute asthmatic bronchitis.Methods A total of 82 children with acute asthmatic bronchitis admitted to the First People's Hospital of Mengcheng County Bozhou City,Anhui Province from January 2020 to January 2023 were selected as the research objects.They were divided into control group and study group by random number table method,with 41 cases in each group.The control group was treated with budesonide aerosol inhalation,and the study group was treated with ipratropium bromide on the basis of the control group.The clinical efficacy,improvement of clinical symptoms,immune function and adverse reactions of the children were evaluated.Results The clinical effect of the study group was significantly higher than that of the control group(P<0.05).The disappearance time of cough,asthma,wheezing and moist rales in the study group was significantly shorter than that in the control group(P<0.05).There was no significant difference in the levels of immune function indexes between groups before treatment(P>0.05).After treatment,the levels of CD3^(+),CD4^(+),CD4^(+)/CD8^(+)in the study group were significantly higher than those of the control group(P<0.05),while the level of CD8+was significantly lower than the control group(P<0.05).Although the incidence of adverse events was lower in the study group than that of the control group,there was no significant difference between the two groups(P>0.05).Conclusion Ipratropium bromide combined with budesonide in the treatment of children with acute asthmatic bronchitis has an ideal clinical efficacy and high safety,which can effectively relieve clinical symptoms and signs,improve immune function and promote quality of life.The combination therapy has a high clinical application value.
作者
李梦梦
丁晓静
王瑞
LI Mengmeng;DING Xiaojing;WANG Rui(Department of Pediatrics,Mengcheng No.1 People’s Hospital,Anhui,Mengcheng 233500,China)
出处
《河北医药》
CAS
2024年第23期3623-3626,共4页
Hebei Medical Journal
基金
安徽省医学会急诊临床研究项目(编号:Ky2018008)。
